GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Edgewise Therapeutics Inc (NAS:EWTX) » Definitions » Cash Ratio

Edgewise Therapeutics (Edgewise Therapeutics) Cash Ratio : 18.98 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Edgewise Therapeutics Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Edgewise Therapeutics's Cash Ratio for the quarter that ended in Dec. 2023 was 18.98.

Edgewise Therapeutics has a Cash Ratio of 18.98. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Edgewise Therapeutics's Cash Ratio or its related term are showing as below:

EWTX' s Cash Ratio Range Over the Past 10 Years
Min: 18.98   Med: 21.22   Max: 29.73
Current: 18.98

During the past 5 years, Edgewise Therapeutics's highest Cash Ratio was 29.73. The lowest was 18.98. And the median was 21.22.

EWTX's Cash Ratio is ranked better than
93.37% of 1524 companies
in the Biotechnology industry
Industry Median: 2.93 vs EWTX: 18.98

Edgewise Therapeutics Cash Ratio Historical Data

The historical data trend for Edgewise Therapeutics's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edgewise Therapeutics Cash Ratio Chart

Edgewise Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
20.89 29.73 26.69 21.22 18.98

Edgewise Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.22 25.79 21.52 17.73 18.98

Competitive Comparison of Edgewise Therapeutics's Cash Ratio

For the Biotechnology subindustry, Edgewise Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edgewise Therapeutics's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Edgewise Therapeutics's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Edgewise Therapeutics's Cash Ratio falls into.



Edgewise Therapeutics Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Edgewise Therapeutics's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=318.393/16.771
=18.98

Edgewise Therapeutics's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=318.393/16.771
=18.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Edgewise Therapeutics  (NAS:EWTX) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Edgewise Therapeutics Cash Ratio Related Terms

Thank you for viewing the detailed overview of Edgewise Therapeutics's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Edgewise Therapeutics (Edgewise Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3415 Colorado Avenue, Boulder, CO, USA, 80303
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
Executives
John R Moore officer: General Counsel 3200 WALNUT ST, BOULDER CO 80301
Alan J Russell director, officer: Chief Scientific Officer 3415 COLORADO AVE, BOULDER CO 80303
Jonathan C Fox director C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
R Michael Carruthers officer: Chief Financial Officer 3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Behrad Derakhshan officer: Chief Business Officer 3415 COLORADO AVE., BOULDER CO 80303
Kevin Koch director, officer: President and CEO 3200 WALNUT ST, BOULDER CO 80301
Joanne M. Donovan officer: CMO C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ. BLDG. 1400E SUITE B14202, CAMBRIDGE MA 02139
Marc Semigran officer: Chief Development Officer C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson director, 10 percent owner C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Orbimed Capital Gp Vi Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jonathan D Root director 2735 SAND HILL ROAD, MENLO PARK CA 94025
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017